 |
ArchiveSelect Stem Cell Stocks Surge After Favorable Court Ruling (PSTI, STEM, ATHX, ASTM, GERN, CUR, NBS, OSIR)Posted by Todd Shriber at 12:41PM on May 2nd
A ruling by federal appeals court last Friday allowing for continued government funding of human embryonic stem cell research is proving to be a major catalyst for select stem cells stocks, led by Pluristem Therapeutic (PSTI), which is surging 6%. Rival…  Pluristem Shoots Higher On ‘Buy’ Rating (PSTI, ASTM, BTX, STEM, ATHX, CYTX, GERN)Posted by Todd Shriber at 12:01PM on January 10th
Pluristem Therapeutic (PSTI), the Israel-based bio-therapeutics firm, is up 13% today after National Securities initiated coverage of the maker of cell therapy products with a “buy” rating. National Securities is bullish on Pluristem’s cell delivery and homing capabilities and sees a… Stem Cell Stocks In Focus After Geron Publications (GERN, BTX, PSTI, ASTM, STEM, ISCO, KOOL, CUR)Posted by Jason Smith at 10:13AM on November 11th
Stem cell research firm Geron (GERN) spiked by 3% on Thursday after announcing two publications demonstrating that its clinical stage imetelstat drug targets cancer stem cells. Imetelstat, according to a company press release, is designed to inhibit telomerase, an enzyme that… Stocks Post Modest Gains On Slow News Ahead of Fed (CHK, CEO, GERN, GYMB, LDK)Posted by Geoff Seiler at 5:07PM on October 11th
Stocks had a quiet day on a slow news Monday, and the major indexes edged up slightly. Investors are eying the Fed, and will be paying close attention to tomorrow’s FOMC minutes, which are due out at 2pm. The Chinese Solar… Geron Rallies as Human Testing Begins (GERN, ISCO, KOOL, ASTM)Posted by Owen Vater at 10:22AM on October 11th
Geron (GERN) said this morning that it has initiated the first human trial of its human embryonic stem cell (hESC)-derived treatment for spinal cord injury, marking the first known use of a hESC therapy on a human patient. President and CEO… Stem Cell Shares Rally On Court of Appeals Ruling (STEM, KOOL, CUR, ATHX, GERN)Posted by Jason Smith at 3:35PM on September 29th
The U.S. Court of Appeals lifted a ban on federally funded embryonic stem cell research on Tuesday, sending select components of the sector higher on domestic exchanges during Wednesday’s session. Back in August, District Judge Royce Lamberth hit the brakes… Did Dendreon Open Doors For Opexa Partnerships? (OPXA, NVS, DNDN, CUR, OSIR, BTIM, NBS, GERN)Posted by Jason Smith at 2:10PM on September 13th
Micro-cap stem cell research firm Opexa Therapeutics (OPXA) surged higher by 70% on Monday, ahead of the firm’s presentation at the Rodman & Renshaw healthcare conference tomorrow. This morning, boutique research firm Vista Partners issued the stock a $4.40 price target,… Stem Cell Shares Pop On Government Action (GERN, PSTI, STEM, CYTX, STEM, OPXA)Posted by Jason Smith at 12:34PM on September 9th
Recent legal disputes have put the stem cell sector in focus after District Judge Royce Lamberth hit the brakes on an executive order from the Obama administration, which had initially opened the door to federally funded research on human embryonic… Investors Eye Stem Cell Shares Amid Court Dispute (GERN, CYTX, OSIR, OPXA, ASTM, ATHX)Posted by Owen Vater at 9:15AM on August 26th
Earlier this week, U.S. District Judge Royce Lamberth hit the brakes an executive order aimed to remove “barriers to responsible research involving human stem cells,” by ruling that millions in government grants can’t be made. Late in 2009, the Obama… StemCells Spikes On Study Results (STEM, CYTX, GERN, ASTM)Posted by Owen Vater at 10:37AM on August 19th
In a preclinical study, Palo Alto, California-based stem cell research firm StemCells (STEM) demonstrated that its proprietary human neural stem cells can restore motor function in the hind legs of paralyzed mice. According to the company announcement, it is the first…  |
|
Follow us on
  |
| Home | Find | Research | Track | Register | My Account | Logout | Web site design by LightMix |
| © 2007-2013 Indie research Corp. All rights reserved. |